查看购物车
  • Traditional Chinese
  • English
  • Japanese
  • Korean
封面
市场调查报告书
商品编码
1870750

急性肺损伤治疗市场按药物类别、给药途径、最终用户、通路、患者年龄层和治疗环境划分－2025-2032年全球预测

Acute Lung Injury Treatment Market by Drug Class, Administration Route, End User, Distribution Channel, Patient Age Group, Treatment Setting - Global Forecast 2025-2032
出版日期: | 出版商: 360iResearch | 英文 181 Pages | 商品交期: 最快1-2个工作天内

价格

※ 本网页内容可能与最新版本有所差异。详细情况请与我们联繫。

预计到 2032 年，急性肺损伤治疗市场将成长至 45.2 亿美元，复合年增长率为 4.31%。

关键市场统计数据
基准年 2024 32.2亿美元
预计年份：2025年 33.6亿美元
预测年份 2032 45.2亿美元
复合年增长率 (%) 4.31%

本文全面概述了急性肺损伤的临床挑战和治疗重点，为相关人员提供指南，以製定循证治疗和交付路径。

急性肺损伤仍然是加护治疗和危重症监护领域的核心临床挑战，促使人们致力于改进治疗方法、优化诊疗路径，并将不断更新的实证医学证据融入临床实践。本导论透过综合阐述当前临床要务，为减少人工呼吸器相关性损伤、控制发炎、增强肺泡功能以及预防常伴随严重呼吸功能障碍发生的器官衰竭级联反应奠定了基础。它将治疗药物类别、给药途径、医疗环境和分销框架置于一个切实可行的决策框架中，旨在为临床医生、医院管理者、支付方和生命科学经营团队提供直接的参考。

临床进展、不断发展的医疗服务模式和现代分销方式的融合如何重塑急性肺损伤治疗的发展和医院的应用

急性肺损伤的治疗格局正经历着一场变革性的转变，这主要得益于药物研发的进步、临床指南的不断完善以及高风险重症医疗机构护理模式的改变。对发炎路径和肺泡修復机制的新认识正在重塑现有药物的理论基础，促使人们重新思考皮质类固醇的给药策略，并日益关注辅助性肺功能调节。同时，通气策略和镇静通讯协定的改进正在影响床边药物介入的实施，并为那些与现代呼吸照护通讯协定具有协同作用的治疗方法方法创造了机会。

评估关税引发的供应链压力如何推动急性肺损伤治疗的多元化、近岸外包和供应连续性策略

关税的实施使得人们更加关注用于急性肺损伤治疗的药品原料和成品的供应链设计、製造地选择和筹资策略。传统上依赖地理位置集中化生产的公司正在重新评估供应商多元化策略，以降低关税风险和清关复杂性。对许多相关人员，这促使他们重新重视近岸外包方案、原料药（API）的双重筹资策略以及能够预见跨国成本波动的合约条款。

按药物类别、给药途径、临床环境和通路进行详细的細項分析，将临床应用与营运执行联繫起来。

细分市场分析揭示了不同药物类别、给药途径、终端用户画像、分销管道、患者人口统计特征和治疗环境之间存在不同的需求驱动因素和营运考虑。在所有药物类别中，皮质类固醇类药物因其抗发炎特性而备受关注，尤其是地塞米松、Hydrocortisone和Methylprednisolone等药物。同时，顺式阿曲库铵、罗库溴铵和维库溴铵等神经肌肉阻断剂仍是促进肺部保护性通气的重要工具。肺表面活性物质疗法，例如贝拉坦和波拉坦α等药物，在某些临床情况下仍然十分重要，因为调节肺泡表面张力可以带来临床获益；吸入性血管扩张剂，例如一氧化氮，则被用作辅助治疗，以改善难治性低氧血症患者的氧合。

对影响全球急性肺损伤治疗普及的区域医疗服务模式、监管趋势和供应链进行比较分析

区域趋势将影响全球主要区域急性肺损伤加护病房的临床实践模式、监管参与和商业性策略。在美洲，整合的医院网络和完善的三级医疗机构推动了对强调快速转入重症监护室管理的通讯协定的需求，这些方案需要先进的人工呼吸器技术和完善的重症监护室药房基础设施的支持。这些特点有利于那些能够与复杂的治疗路径无缝衔接，并能调动医院处方集委员会和加护治疗学会等相关人员的治疗方法方案。

策略性企业专注于临床证据、生产韧性和伙伴关係模式，以加强急性肺损伤的治疗服务。

在公司层面，我们看到企业正加大对临床开发、生产韧性和合作伙伴关係的策略性投资，以加速临床应用并加强供应连续性。领先的药物研发企业优先考虑证明药物与现代呼吸器和镇静通讯协定相容性的证据，同时也在投资于製剂创新和包装技术，以实现在急诊环境中快速给药。製造商与合约研发生产机构（CDMO）之间的策略联盟日益普遍，旨在提高生产灵活性并支持地理多元化。

製造商和医疗保健领导者可采取的切实可行的策略挑战，以增强临床应用、供应链韧性和整合式护理路径

产业领导者应优先采取一系列切实可行的措施，以提高急性肺损伤治疗的临床疗效、供应稳定性和商业性效益。首先，应使临床开发和上市后证据项目与现代加护治疗实践相契合，设计的研究应反映现代通气策略、常见合併症以及对临床医生和医院处方委员会至关重要的可操作终点。这将有助于缩小监管核准与实际效用之间的证据差距，从而加快产品推广应用并优化治疗路径。

采用稳健的混合调查方法，结合证据综合、相关人员访谈和供应链分析，得出具有临床指导意义的研究结果。

本分析的调查方法结合了系统性的证据综合、与关键相关利益者的直接对话以及严格的资料交叉检验，以确保其可靠性和相关性。此方法首先透过全面审查同行评审的临床文献、监管核准和产品资讯以及公开的临床试验註册库，为相关治疗领域建立临床证据和安全性概况的基础。其次，对加护治疗、医院药局主任和采购人员进行结构化访谈，以深入了解通讯协定选择趋势、营运限制和实施障碍等方面的实际情况。

将治疗方面的进展转化为患者疗效的可衡量改善，需要整合和协调临床、营运和供应链方面的要求。

总之，推进急性肺损伤治疗需要在临床证据累积、运作执行和供应链韧性方面取得协同进展。皮质类固醇、神经肌肉阻断剂、界面活性剂和血管扩张剂等治疗药物在现代治疗模式中各自发挥不同的作用，其有效应用取决于给药途径、护理环境和配送模式是否符合急性护理的实际情况。应对关税和区域监管差异造成的供应脆弱性，需要采取更积极主动的筹资策略和社区层面的努力，以确保患者能够持续获得治疗。

目录

第一章：序言

第二章调查方法

第三章执行摘要

第四章 市场概览

第五章 市场洞察

  • 基于新兴生物标记的个人化治疗在急性肺损伤管理的应用
  • 采用照护现场超音波通讯协定优化急性肺损伤患者的液体管理
  • 间质干细胞疗法治疗急性呼吸窘迫症候群的临床试验进展
  • 整合人工智慧驱动的预测分析技术以早期发现急性肺损伤风险
  • 针对急性肺损伤的新型吸入抗发炎药物的快速监管核准流程
  • 引入远端ICU平台以支援急性肺损伤患者的人工呼吸器加护病房策略
  • 开发体外二氧化碳清除系统以改善重症急性肺损伤的治疗效果
  • 穿戴式生物感测器在高风险患者中广泛用于连续呼吸监测
  • 一项真实世界证据研究评估了高流量氧气鼻管在中度至重度急性肺损伤 (ALI) 中的疗效。
  • 与製药公司进行合作研究，重点在于用于治疗肺部发炎的脂质奈米颗粒药物递送系统。

第六章：美国关税的累积影响，2025年

第七章：人工智慧的累积影响，2025年

8. 急性肺损伤治疗市场（依药物类别划分）

  • 皮质类固醇
    • 地塞米松
    • Hydrocortisone
    • Methylprednisolone
  • 神经肌肉阻断剂
    • 顺式曲库铵
    • 罗库溴铵
    • 维库溴铵
  • 界面活性剂
    • 维拉克坦
    • 猪粪α
  • 血管扩张剂
    • 一氧化氮

9. 依给药途径分類的急性肺损伤治疗市场

  • 吸入
  • 静脉注射

第十章 按最终用户分類的急性肺损伤治疗市场

  • 门诊治疗中心
  • 医院
  • 研究所

第十一章 急性肺损伤治疗市场（依通路划分）

  • 医院药房
    • 住院药房
    • 门诊药房
  • 网路药房
    • 直接送达患者
    • 第三方履约
  • 零售药房
    • 连锁药局
    • 独立药房

第十二章 依患者年龄组别分類的急性肺损伤治疗市场

  • 成人
  • 老年人
  • 儿童

第十三章 急性肺损伤治疗市场：依治疗场所划分

  • 急诊室
  • 普通病房
  • 加护病房

第十四章 急性肺损伤治疗市场：依地区划分

  • 美洲
    • 北美洲
    • 拉丁美洲
  • 欧洲、中东和非洲
    • 欧洲
    • 中东
    • 非洲
  • 亚太地区

第十五章 急性肺损伤治疗市场（依组别划分）

  • ASEAN
  • GCC
  • EU
  • BRICS
  • G7
  • NATO

第十六章 各国急性肺损伤治疗市场

  • 美国
  • 加拿大
  • 墨西哥
  • 巴西
  • 英国
  • 德国
  • 法国
  • 俄罗斯
  • 义大利
  • 西班牙
  • 中国
  • 印度
  • 日本
  • 澳洲
  • 韩国

第十七章 竞争格局

  • 2024年市占率分析
  • FPNV定位矩阵，2024
  • 竞争分析
    • Medtronic plc
    • Koninklijke Philips NV
    • General Electric Company
    • Dragerwerk AG & Co. KGaA
    • Fisher & Paykel Healthcare Corporation Limited
    • Hamilton Medical AG
    • Smiths Group plc
    • Getinge AB
    • Vyaire Medical, Inc.
    • Nihon Kohden Corporation
Product Code: MRR-1A1A064C0344

The Acute Lung Injury Treatment Market is projected to grow by USD 4.52 billion at a CAGR of 4.31% by 2032.

KEY MARKET STATISTICS
Base Year [2024] USD 3.22 billion
Estimated Year [2025] USD 3.36 billion
Forecast Year [2032] USD 4.52 billion
CAGR (%) 4.31%

Comprehensive framing of acute lung injury clinical challenges and therapeutic priorities to orient stakeholders toward evidence-based treatment and delivery pathways

Acute lung injury remains a central clinical challenge across critical care and emergency medicine, prompting intensive efforts to refine therapeutic approaches, optimize care pathways, and integrate evolving evidence into practice. This introduction frames the landscape by synthesizing the prevailing clinical imperatives: reducing ventilator-associated injury, managing inflammation, enhancing alveolar function, and attenuating the cascade of organ dysfunction that often accompanies severe respiratory compromise. It situates therapeutic classes, administration routes, care settings, and distribution frameworks within a practical decision-making context that speaks directly to clinicians, hospital leaders, payers, and life sciences executives.

Transitioning from clinical priorities to system-level implications, this section underscores how multidisciplinary coordination, supply chain resilience, and regulatory clarity are shaping implementation timelines for novel and repurposed interventions. It highlights the need for integrated protocols that reconcile pharmacologic strategies with ventilatory management and supportive care, while also calling attention to the crucial role of real-world evidence and clinician preference in driving adoption. The introduction sets expectations for the remainder of the report by outlining the analytical lens applied throughout: a synthesis of clinical evidence, regulatory signals, stakeholder interviews, and distribution dynamics intended to support informed strategic choices.

How converging clinical advances, care delivery evolution, and distribution modernization are reshaping acute lung injury therapeutic development and hospital adoption

The therapeutic landscape for acute lung injury is undergoing transformative shifts driven by advances in drug development, evolving clinical guidelines, and changes in care delivery models within high-acuity environments. Novel insights into the inflammatory pathways and alveolar repair mechanisms are reshaping the rationale for existing drug classes, prompting reconsideration of corticosteroid dosing strategies and renewed interest in adjunctive agents that modulate pulmonary mechanics. Concurrently, precision in ventilation strategies and sedation protocols is influencing how pharmacologic interventions are deployed at the bedside, creating opportunities for therapies that demonstrate synergy with contemporary respiratory care protocols.

In parallel, the commercialization and distribution environment is adapting to digital enablement, inventory optimization, and heightened scrutiny of supply continuity. These forces drive greater collaboration between manufacturers, hospital pharmacies, and specialty distributors, while also elevating the importance of value demonstration and post-market evidence generation. Regulatory pathways are increasingly emphasizing robust safety monitoring and real-world performance data, which in turn informs payer and hospital procurement expectations. Together, these dynamics are producing a landscape that rewards integrated evidence generation, nimble manufacturing practices, and clinically meaningful differentiation across treatment modalities.

Assessing how tariff-driven supply chain pressures are prompting diversification, nearshoring, and supply continuity strategies for acute lung injury therapeutics

The imposition of tariffs has heightened attention on supply chain design, manufacturing footprint decisions, and sourcing strategies for pharmaceutical inputs and finished formulations used in acute lung injury treatment. Companies that historically relied on geographically concentrated manufacturing are reassessing supplier diversification to mitigate tariff exposure and customs complexity. For many stakeholders, this has translated into a renewed emphasis on nearshoring options, dual-sourced active pharmaceutical ingredient (API) strategies, and contractual clauses that anticipate cross-border cost volatility.

Operational responses have included increased inventory buffers at hospital pharmacies coupled with closer collaboration between procurement teams and manufacturers to stabilize lead times and ensure continuity of care. Regulatory and quality oversight remain central to any sourcing shift, so firms pursuing alternative manufacturing arrangements prioritize established regulatory credentials and transparent audit trails. From a clinical perspective, continuity of access to established agents such as corticosteroids and neuromuscular blocking agents has been paramount, prompting contingency planning that aligns therapeutic protocols with available product formats and validated interchangeability strategies. Collectively, these adaptations underscore the importance of resilient supply networks and proactive stakeholder engagement in preserving treatment pathways amid tariff-driven disruptions.

In-depth segmentation insights linking drug classes, administration routes, care settings, and distribution channels to clinical application and operational execution

Segmentation analysis reveals differentiated demand drivers and operational considerations across drug classes, routes of administration, end-user profiles, distribution channels, patient age groups, and treatment settings. Across drug classes, corticosteroids command strategic attention with specific focus on agents such as dexamethasone, hydrocortisone, and methylprednisolone for their anti-inflammatory profiles, while neuromuscular blocking agents including cisatracurium, rocuronium, and vecuronium remain essential tools to facilitate lung-protective ventilation. Surfactant therapy, represented by agents like beractant and poractant alfa, continues to be critical in selected clinical scenarios where alveolar surface tension modulation offers clinical benefit, and inhaled vasodilators such as nitric oxide are deployed as adjuncts to improve oxygenation in refractory hypoxemia.

Route of administration drives logistical and clinical choices, with inhalation and intravenous options each presenting unique efficacy, onset, and safety trade-offs that inform protocol selection in the emergency department, general ward, or intensive care unit. End-user segmentation differentiates ambulatory care centers, hospitals, and research institutes by their clinical throughput, procedural capabilities, and research priorities, which in turn shapes expectations around product formats and support services. Distribution channel dynamics span hospital pharmacies, online pharmacies, and retail pharmacies; within hospital pharmacy operations, inpatient and outpatient pharmacy divisions have distinct inventory and dispensing workflows, while online channels include direct-to-patient and third-party fulfillment models that require careful cold-chain and regulatory compliance planning. Chain and independent retail pharmacies also play roles in outpatient transitions of care and patient access programs. Patient age group segmentation into adult, geriatric, and pediatric cohorts highlights dosing, safety, and formulation considerations that influence clinical decision-making and packaging design. Lastly, treatment setting segmentation across emergency departments, general wards, and intensive care units affects time-to-therapy imperatives, monitoring requirements, and interdisciplinary coordination needs, making alignment between therapeutic attributes and care environment essential for successful implementation.

Comparative regional analysis of care delivery models, regulatory dynamics, and supply chain considerations shaping acute lung injury treatment adoption globally

Regional dynamics shape clinical practice patterns, regulatory interactions, and commercial approaches for acute lung injury therapeutics across major global corridors. In the Americas, integrated hospital networks and a high degree of tertiary care capacity drive demand for protocols that emphasize rapid escalation to intensive care unit management, supported by advanced ventilatory technologies and established ICU pharmacy infrastructures. These characteristics favor therapies that integrate seamlessly with complex care pathways and where stakeholder engagement includes hospital formulary committees and critical care societies.

Europe, the Middle East & Africa encompasses a heterogeneous set of health systems, regulatory frameworks, and procurement models, which necessitates tailored market access strategies that account for national reimbursement mechanisms and region-specific clinical guidelines. Variability in critical care capacity and supply chain infrastructure in parts of this region can influence prioritization of stable supply channels and simplified administration profiles. Asia-Pacific features a mix of high-capacity urban tertiary centers and rapidly expanding regional care networks, with certain markets demonstrating accelerated adoption of digital health tools and tele-ICU models. In several parts of the region, manufacturing capacity and API production are significant factors that shape commercial negotiations and collaboration opportunities, and partnerships that address local clinical training and evidence generation often facilitate more rapid clinical integration. Across all regions, aligning regulatory strategy, evidence generation, and supply continuity plans with local clinical expectations remains central to successful implementation.

Strategic corporate priorities focusing on clinical evidence, manufacturing resilience, and partnership models to strengthen acute lung injury therapeutic delivery

Company-level dynamics are characterized by strategic investments in clinical development, manufacturing resilience, and collaborative partnerships that accelerate clinical adoption and strengthen supply continuity. Leading pharmaceutical developers are prioritizing evidence generation that demonstrates compatibility with contemporary ventilation and sedation protocols, while also investing in formulation innovations and packaging that facilitate rapid administration in acute care settings. Strategic alliances between manufacturers and contract development and manufacturing organizations are increasingly common to enhance scale flexibility and to support geographic diversification of production.

Commercially, companies are enhancing clinician engagement through targeted medical education, disease-state awareness initiatives, and real-world evidence programs that capture outcomes associated with varied treatment regimens. On the supply side, organizations are implementing advanced demand planning tools, serialized traceability, and quality-by-design practices to mitigate disruption risk and to satisfy heightened regulatory expectations. Additionally, some companies are expanding service offerings around patient support and hospital pharmacy integration to secure smoother transitions from acute care to outpatient follow-up. Collectively, these corporate strategies emphasize the integration of clinical relevance, operational robustness, and commercial agility to maintain continuity of care and to support evidence-informed decision-making across stakeholders.

Actionable strategic imperatives for manufacturers and healthcare leaders to strengthen clinical adoption, supply resilience, and integrated care pathways

Industry leaders should prioritize a set of pragmatic actions to enhance clinical impact, supply resilience, and commercial effectiveness for acute lung injury treatments. First, align clinical development and post-market evidence programs with contemporary critical care practice by designing studies that reflect modern ventilation strategies, common comorbidities, and pragmatic endpoints that matter to clinicians and hospital formulary committees. By doing so, organizations can reduce the evidence gap between regulatory approval and real-world clinical utility, supporting more rapid uptake and optimized care pathways.

Second, invest in diversified manufacturing and procurement strategies that balance cost efficiency with supply continuity, including dual sourcing of critical APIs, evaluation of nearshore production opportunities, and strengthened quality oversight across contract manufacturing partners. Third, deepen engagement with hospital pharmacy leaders, critical care clinicians, and procurement teams to co-design implementation protocols that address dosing convenience, storage constraints, and monitoring requirements across emergency departments, general wards, and intensive care units. Fourth, enhance digital and data infrastructure to capture real-world outcomes, support pharmacovigilance, and generate actionable insights for continuous improvement. Finally, develop flexible commercial models that consider hospital formulary dynamics and reimbursement environments, offering bundled service propositions and education programs that lower barriers to adoption while demonstrating clear operational benefits.

Robust mixed-methods research approach combining evidence synthesis, stakeholder interviews, and supply chain analysis to deliver clinically actionable insights

The research methodology underpinning this analysis combines systematic evidence synthesis, primary stakeholder engagement, and rigorous cross-validation of data to ensure reliability and relevance. The approach begins with comprehensive reviews of peer-reviewed clinical literature, regulatory approvals and labeling information, and publicly available clinical trial registries to establish a foundation of clinical evidence and safety profiles for the relevant therapeutic classes. This evidence base is then complemented by structured interviews with critical care clinicians, hospital pharmacy directors, and procurement leaders to surface practical insights about protocol preferences, operational constraints, and adoption barriers.

To capture distribution and operational dynamics, the methodology incorporates analysis of supply chain architectures, distribution channel practices, and regulatory compliance requirements, with particular attention to product formats and cold-chain considerations where relevant. Quality assurance steps include triangulation across multiple information sources, validation of key findings with subject matter experts, and sensitivity checks to ensure conclusions remain robust across divergent clinical and operational scenarios. Throughout, the research prioritizes transparency in data sources and methodological assumptions and emphasizes actionable interpretation to support decision-making by clinical, commercial, and operational stakeholders.

Synthesis of clinical, operational, and supply chain imperatives that must align to translate therapeutic advances into measurable improvements in patient outcomes

In conclusion, advancing the treatment of acute lung injury requires coordinated progress across clinical evidence generation, operational execution, and supply chain resilience. Therapeutic classes including corticosteroids, neuromuscular blocking agents, surfactants, and vasodilators each play defined roles within contemporary treatment paradigms, and their effective deployment depends on alignment with administration routes, care settings, and distribution models that meet the realities of acute care delivery. Addressing tariff-induced supply vulnerabilities and regional regulatory heterogeneity further necessitates proactive sourcing strategies and localized engagement to ensure uninterrupted patient access.

Moving forward, stakeholders who invest in pragmatic evidence generation, clinician-centered implementation design, and manufacturing flexibility will be best positioned to translate scientific advances into meaningful improvements in patient outcomes. Coordination across hospital systems, suppliers, and regulatory bodies remains essential to harmonize expectations and to streamline pathways from therapy availability to routine clinical use. Ultimately, the integration of rigorous clinical data, resilient operations, and collaborative stakeholder engagement will determine the trajectory of therapeutic impact for patients experiencing acute lung injury.

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Segmentation & Coverage
  • 1.3. Years Considered for the Study
  • 1.4. Currency & Pricing
  • 1.5. Language
  • 1.6. Stakeholders

2. Research Methodology

3. Executive Summary

4. Market Overview

5. Market Insights

  • 5.1. Emerging biomarker-guided personalized therapies for acute lung injury management
  • 5.2. Adoption of point-of-care ultrasound protocols to optimize fluid management in ALI patients
  • 5.3. Clinical trial advancements in mesenchymal stem cell therapies targeting acute respiratory distress syndrome
  • 5.4. Integration of AI-driven predictive analytics for early detection of acute lung injury risk
  • 5.5. Regulatory approval pathways expediting novel inhaled anti-inflammatory agents for ALI
  • 5.6. Implementation of tele-ICU platforms to support ventilator weaning strategies in acute lung injury
  • 5.7. Development of extracorporeal carbon dioxide removal systems improving outcomes in severe ALI
  • 5.8. Expansion of wearable biosensors for continuous respiratory monitoring in high-risk patients
  • 5.9. Real-world evidence studies evaluating high-flow nasal cannula efficacy in moderate to severe ALI
  • 5.10. Pharmaceutical collaborations focusing on lipid nanoparticle drug delivery for pulmonary inflammation

6. Cumulative Impact of United States Tariffs 2025

7. Cumulative Impact of Artificial Intelligence 2025

8. Acute Lung Injury Treatment Market, by Drug Class

  • 8.1. Corticosteroids
    • 8.1.1. Dexamethasone
    • 8.1.2. Hydrocortisone
    • 8.1.3. Methylprednisolone
  • 8.2. Neuromuscular Blocking Agents
    • 8.2.1. Cisatracurium
    • 8.2.2. Rocuronium
    • 8.2.3. Vecuronium
  • 8.3. Surfactants
    • 8.3.1. Beractant
    • 8.3.2. Poractant Alfa
  • 8.4. Vasodilators
    • 8.4.1. Nitric Oxide

9. Acute Lung Injury Treatment Market, by Administration Route

  • 9.1. Inhalation
  • 9.2. Intravenous

10. Acute Lung Injury Treatment Market, by End User

  • 10.1. Ambulatory Care Centers
  • 10.2. Hospitals
  • 10.3. Research Institutes

11. Acute Lung Injury Treatment Market, by Distribution Channel

  • 11.1. Hospital Pharmacies
    • 11.1.1. Inpatient Pharmacies
    • 11.1.2. Outpatient Pharmacies
  • 11.2. Online Pharmacies
    • 11.2.1. Direct To Patient
    • 11.2.2. Third Party Fulfillment
  • 11.3. Retail Pharmacies
    • 11.3.1. Chain Pharmacies
    • 11.3.2. Independent Pharmacies

12. Acute Lung Injury Treatment Market, by Patient Age Group

  • 12.1. Adult
  • 12.2. Geriatric
  • 12.3. Pediatric

13. Acute Lung Injury Treatment Market, by Treatment Setting

  • 13.1. Emergency Department
  • 13.2. General Ward
  • 13.3. Intensive Care Unit

14. Acute Lung Injury Treatment Market, by Region

  • 14.1. Americas
    • 14.1.1. North America
    • 14.1.2. Latin America
  • 14.2. Europe, Middle East & Africa
    • 14.2.1. Europe
    • 14.2.2. Middle East
    • 14.2.3. Africa
  • 14.3. Asia-Pacific

15. Acute Lung Injury Treatment Market, by Group

  • 15.1. ASEAN
  • 15.2. GCC
  • 15.3. European Union
  • 15.4. BRICS
  • 15.5. G7
  • 15.6. NATO

16. Acute Lung Injury Treatment Market, by Country

  • 16.1. United States
  • 16.2. Canada
  • 16.3. Mexico
  • 16.4. Brazil
  • 16.5. United Kingdom
  • 16.6. Germany
  • 16.7. France
  • 16.8. Russia
  • 16.9. Italy
  • 16.10. Spain
  • 16.11. China
  • 16.12. India
  • 16.13. Japan
  • 16.14. Australia
  • 16.15. South Korea

17. Competitive Landscape

  • 17.1. Market Share Analysis, 2024
  • 17.2. FPNV Positioning Matrix, 2024
  • 17.3. Competitive Analysis
    • 17.3.1. Medtronic plc
    • 17.3.2. Koninklijke Philips N.V.
    • 17.3.3. General Electric Company
    • 17.3.4. Dragerwerk AG & Co. KGaA
    • 17.3.5. Fisher & Paykel Healthcare Corporation Limited
    • 17.3.6. Hamilton Medical AG
    • 17.3.7. Smiths Group plc
    • 17.3.8. Getinge AB
    • 17.3.9. Vyaire Medical, Inc.
    • 17.3.10. Nihon Kohden Corporation

LIST OF FIGURES

  • FIGURE 1. GLOBAL ACUTE LUNG INJURY TREATMENT MARKET SIZE, 2018-2032 (USD MILLION)
  • FIGURE 2. GLOBAL ACUTE LUNG INJURY TREATMENT MARKET SIZE, BY DRUG CLASS, 2024 VS 2032 (%)
  • FIGURE 3. GLOBAL ACUTE LUNG INJURY TREATMENT MARKET SIZE, BY DRUG CLASS, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 4. GLOBAL ACUTE LUNG INJURY TREATMENT MARKET SIZE, BY ADMINISTRATION ROUTE, 2024 VS 2032 (%)
  • FIGURE 5. GLOBAL ACUTE LUNG INJURY TREATMENT MARKET SIZE, BY ADMINISTRATION ROUTE, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 6. GLOBAL ACUTE LUNG INJURY TREATMENT MARKET SIZE, BY END USER, 2024 VS 2032 (%)
  • FIGURE 7. GLOBAL ACUTE LUNG INJURY TREATMENT MARKET SIZE, BY END USER, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 8. GLOBAL ACUTE LUNG INJURY TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024 VS 2032 (%)
  • FIGURE 9. GLOBAL ACUTE LUNG INJURY TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 10. GLOBAL ACUTE LUNG INJURY TREATMENT MARKET SIZE, BY PATIENT AGE GROUP, 2024 VS 2032 (%)
  • FIGURE 11. GLOBAL ACUTE LUNG INJURY TREATMENT MARKET SIZE, BY PATIENT AGE GROUP, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 12. GLOBAL ACUTE LUNG INJURY TREATMENT MARKET SIZE, BY TREATMENT SETTING, 2024 VS 2032 (%)
  • FIGURE 13. GLOBAL ACUTE LUNG INJURY TREATMENT MARKET SIZE, BY TREATMENT SETTING, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 14. GLOBAL ACUTE LUNG INJURY TREATMENT MARKET SIZE, BY REGION, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 15. AMERICAS ACUTE LUNG INJURY TREATMENT MARKET SIZE, BY SUBREGION, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 16. NORTH AMERICA ACUTE LUNG INJURY TREATMENT MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 17. LATIN AMERICA ACUTE LUNG INJURY TREATMENT MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 18. EUROPE, MIDDLE EAST & AFRICA ACUTE LUNG INJURY TREATMENT MARKET SIZE, BY SUBREGION, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 19. EUROPE ACUTE LUNG INJURY TREATMENT MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 20. MIDDLE EAST ACUTE LUNG INJURY TREATMENT MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 21. AFRICA ACUTE LUNG INJURY TREATMENT MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 22. ASIA-PACIFIC ACUTE LUNG INJURY TREATMENT MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 23. GLOBAL ACUTE LUNG INJURY TREATMENT MARKET SIZE, BY GROUP, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 24. ASEAN ACUTE LUNG INJURY TREATMENT MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 25. GCC ACUTE LUNG INJURY TREATMENT MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 26. EUROPEAN UNION ACUTE LUNG INJURY TREATMENT MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 27. BRICS ACUTE LUNG INJURY TREATMENT MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 28. G7 ACUTE LUNG INJURY TREATMENT MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 29. NATO ACUTE LUNG INJURY TREATMENT MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 30. GLOBAL ACUTE LUNG INJURY TREATMENT MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 31. ACUTE LUNG INJURY TREATMENT MARKET SHARE, BY KEY PLAYER, 2024
  • FIGURE 32. ACUTE LUNG INJURY TREATMENT MARKET, FPNV POSITIONING MATRIX, 2024

LIST OF TABLES

  • TABLE 1. ACUTE LUNG INJURY TREATMENT MARKET SEGMENTATION & COVERAGE
  • TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2024
  • TABLE 3. GLOBAL ACUTE LUNG INJURY TREATMENT MARKET SIZE, 2018-2024 (USD MILLION)
  • TABLE 4. GLOBAL ACUTE LUNG INJURY TREATMENT MARKET SIZE, 2025-2032 (USD MILLION)
  • TABLE 5. GLOBAL ACUTE LUNG INJURY TREATMENT MARKET SIZE, BY DRUG CLASS, 2018-2024 (USD MILLION)
  • TABLE 6. GLOBAL ACUTE LUNG INJURY TREATMENT MARKET SIZE, BY DRUG CLASS, 2025-2032 (USD MILLION)
  • TABLE 7. GLOBAL ACUTE LUNG INJURY TREATMENT MARKET SIZE, BY CORTICOSTEROIDS, 2018-2024 (USD MILLION)
  • TABLE 8. GLOBAL ACUTE LUNG INJURY TREATMENT MARKET SIZE, BY CORTICOSTEROIDS, 2025-2032 (USD MILLION)
  • TABLE 9. GLOBAL ACUTE LUNG INJURY TREATMENT MARKET SIZE, BY CORTICOSTEROIDS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 10. GLOBAL ACUTE LUNG INJURY TREATMENT MARKET SIZE, BY CORTICOSTEROIDS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 11. GLOBAL ACUTE LUNG INJURY TREATMENT MARKET SIZE, BY CORTICOSTEROIDS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 12. GLOBAL ACUTE LUNG INJURY TREATMENT MARKET SIZE, BY CORTICOSTEROIDS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 13. GLOBAL ACUTE LUNG INJURY TREATMENT MARKET SIZE, BY CORTICOSTEROIDS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 14. GLOBAL ACUTE LUNG INJURY TREATMENT MARKET SIZE, BY CORTICOSTEROIDS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 15. GLOBAL ACUTE LUNG INJURY TREATMENT MARKET SIZE, BY DEXAMETHASONE, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 16. GLOBAL ACUTE LUNG INJURY TREATMENT MARKET SIZE, BY DEXAMETHASONE, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 17. GLOBAL ACUTE LUNG INJURY TREATMENT MARKET SIZE, BY DEXAMETHASONE, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 18. GLOBAL ACUTE LUNG INJURY TREATMENT MARKET SIZE, BY DEXAMETHASONE, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 19. GLOBAL ACUTE LUNG INJURY TREATMENT MARKET SIZE, BY DEXAMETHASONE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 20. GLOBAL ACUTE LUNG INJURY TREATMENT MARKET SIZE, BY DEXAMETHASONE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 21. GLOBAL ACUTE LUNG INJURY TREATMENT MARKET SIZE, BY HYDROCORTISONE, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 22. GLOBAL ACUTE LUNG INJURY TREATMENT MARKET SIZE, BY HYDROCORTISONE, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 23. GLOBAL ACUTE LUNG INJURY TREATMENT MARKET SIZE, BY HYDROCORTISONE, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 24. GLOBAL ACUTE LUNG INJURY TREATMENT MARKET SIZE, BY HYDROCORTISONE, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 25. GLOBAL ACUTE LUNG INJURY TREATMENT MARKET SIZE, BY HYDROCORTISONE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 26. GLOBAL ACUTE LUNG INJURY TREATMENT MARKET SIZE, BY HYDROCORTISONE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 27. GLOBAL ACUTE LUNG INJURY TREATMENT MARKET SIZE, BY METHYLPREDNISOLONE, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 28. GLOBAL ACUTE LUNG INJURY TREATMENT MARKET SIZE, BY METHYLPREDNISOLONE, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 29. GLOBAL ACUTE LUNG INJURY TREATMENT MARKET SIZE, BY METHYLPREDNISOLONE, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 30. GLOBAL ACUTE LUNG INJURY TREATMENT MARKET SIZE, BY METHYLPREDNISOLONE, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 31. GLOBAL ACUTE LUNG INJURY TREATMENT MARKET SIZE, BY METHYLPREDNISOLONE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 32. GLOBAL ACUTE LUNG INJURY TREATMENT MARKET SIZE, BY METHYLPREDNISOLONE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 33. GLOBAL ACUTE LUNG INJURY TREATMENT MARKET SIZE, BY NEUROMUSCULAR BLOCKING AGENTS, 2018-2024 (USD MILLION)
  • TABLE 34. GLOBAL ACUTE LUNG INJURY TREATMENT MARKET SIZE, BY NEUROMUSCULAR BLOCKING AGENTS, 2025-2032 (USD MILLION)
  • TABLE 35. GLOBAL ACUTE LUNG INJURY TREATMENT MARKET SIZE, BY NEUROMUSCULAR BLOCKING AGENTS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 36. GLOBAL ACUTE LUNG INJURY TREATMENT MARKET SIZE, BY NEUROMUSCULAR BLOCKING AGENTS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 37. GLOBAL ACUTE LUNG INJURY TREATMENT MARKET SIZE, BY NEUROMUSCULAR BLOCKING AGENTS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 38. GLOBAL ACUTE LUNG INJURY TREATMENT MARKET SIZE, BY NEUROMUSCULAR BLOCKING AGENTS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 39. GLOBAL ACUTE LUNG INJURY TREATMENT MARKET SIZE, BY NEUROMUSCULAR BLOCKING AGENTS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 40. GLOBAL ACUTE LUNG INJURY TREATMENT MARKET SIZE, BY NEUROMUSCULAR BLOCKING AGENTS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 41. GLOBAL ACUTE LUNG INJURY TREATMENT MARKET SIZE, BY CISATRACURIUM, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 42. GLOBAL ACUTE LUNG INJURY TREATMENT MARKET SIZE, BY CISATRACURIUM, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 43. GLOBAL ACUTE LUNG INJURY TREATMENT MARKET SIZE, BY CISATRACURIUM, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 44. GLOBAL ACUTE LUNG INJURY TREATMENT MARKET SIZE, BY CISATRACURIUM, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 45. GLOBAL ACUTE LUNG INJURY TREATMENT MARKET SIZE, BY CISATRACURIUM, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 46. GLOBAL ACUTE LUNG INJURY TREATMENT MARKET SIZE, BY CISATRACURIUM, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 47. GLOBAL ACUTE LUNG INJURY TREATMENT MARKET SIZE, BY ROCURONIUM, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 48. GLOBAL ACUTE LUNG INJURY TREATMENT MARKET SIZE, BY ROCURONIUM, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 49. GLOBAL ACUTE LUNG INJURY TREATMENT MARKET SIZE, BY ROCURONIUM, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 50. GLOBAL ACUTE LUNG INJURY TREATMENT MARKET SIZE, BY ROCURONIUM, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 51. GLOBAL ACUTE LUNG INJURY TREATMENT MARKET SIZE, BY ROCURONIUM, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 52. GLOBAL ACUTE LUNG INJURY TREATMENT MARKET SIZE, BY ROCURONIUM, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 53. GLOBAL ACUTE LUNG INJURY TREATMENT MARKET SIZE, BY VECURONIUM, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 54. GLOBAL ACUTE LUNG INJURY TREATMENT MARKET SIZE, BY VECURONIUM, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 55. GLOBAL ACUTE LUNG INJURY TREATMENT MARKET SIZE, BY VECURONIUM, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 56. GLOBAL ACUTE LUNG INJURY TREATMENT MARKET SIZE, BY VECURONIUM, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 57. GLOBAL ACUTE LUNG INJURY TREATMENT MARKET SIZE, BY VECURONIUM, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 58. GLOBAL ACUTE LUNG INJURY TREATMENT MARKET SIZE, BY VECURONIUM, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 59. GLOBAL ACUTE LUNG INJURY TREATMENT MARKET SIZE, BY SURFACTANTS, 2018-2024 (USD MILLION)
  • TABLE 60. GLOBAL ACUTE LUNG INJURY TREATMENT MARKET SIZE, BY SURFACTANTS, 2025-2032 (USD MILLION)
  • TABLE 61. GLOBAL ACUTE LUNG INJURY TREATMENT MARKET SIZE, BY SURFACTANTS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 62. GLOBAL ACUTE LUNG INJURY TREATMENT MARKET SIZE, BY SURFACTANTS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 63. GLOBAL ACUTE LUNG INJURY TREATMENT MARKET SIZE, BY SURFACTANTS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 64. GLOBAL ACUTE LUNG INJURY TREATMENT MARKET SIZE, BY SURFACTANTS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 65. GLOBAL ACUTE LUNG INJURY TREATMENT MARKET SIZE, BY SURFACTANTS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 66. GLOBAL ACUTE LUNG INJURY TREATMENT MARKET SIZE, BY SURFACTANTS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 67. GLOBAL ACUTE LUNG INJURY TREATMENT MARKET SIZE, BY BERACTANT, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 68. GLOBAL ACUTE LUNG INJURY TREATMENT MARKET SIZE, BY BERACTANT, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 69. GLOBAL ACUTE LUNG INJURY TREATMENT MARKET SIZE, BY BERACTANT, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 70. GLOBAL ACUTE LUNG INJURY TREATMENT MARKET SIZE, BY BERACTANT, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 71. GLOBAL ACUTE LUNG INJURY TREATMENT MARKET SIZE, BY BERACTANT, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 72. GLOBAL ACUTE LUNG INJURY TREATMENT MARKET SIZE, BY BERACTANT, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 73. GLOBAL ACUTE LUNG INJURY TREATMENT MARKET SIZE, BY PORACTANT ALFA, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 74. GLOBAL ACUTE LUNG INJURY TREATMENT MARKET SIZE, BY PORACTANT ALFA, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 75. GLOBAL ACUTE LUNG INJURY TREATMENT MARKET SIZE, BY PORACTANT ALFA, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 76. GLOBAL ACUTE LUNG INJURY TREATMENT MARKET SIZE, BY PORACTANT ALFA, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 77. GLOBAL ACUTE LUNG INJURY TREATMENT MARKET SIZE, BY PORACTANT ALFA, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 78. GLOBAL ACUTE LUNG INJURY TREATMENT MARKET SIZE, BY PORACTANT ALFA, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 79. GLOBAL ACUTE LUNG INJURY TREATMENT MARKET SIZE, BY VASODILATORS, 2018-2024 (USD MILLION)
  • TABLE 80. GLOBAL ACUTE LUNG INJURY TREATMENT MARKET SIZE, BY VASODILATORS, 2025-2032 (USD MILLION)
  • TABLE 81. GLOBAL ACUTE LUNG INJURY TREATMENT MARKET SIZE, BY VASODILATORS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 82. GLOBAL ACUTE LUNG INJURY TREATMENT MARKET SIZE, BY VASODILATORS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 83. GLOBAL ACUTE LUNG INJURY TREATMENT MARKET SIZE, BY VASODILATORS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 84. GLOBAL ACUTE LUNG INJURY TREATMENT MARKET SIZE, BY VASODILATORS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 85. GLOBAL ACUTE LUNG INJURY TREATMENT MARKET SIZE, BY VASODILATORS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 86. GLOBAL ACUTE LUNG INJURY TREATMENT MARKET SIZE, BY VASODILATORS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 87. GLOBAL ACUTE LUNG INJURY TREATMENT MARKET SIZE, BY NITRIC OXIDE, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 88. GLOBAL ACUTE LUNG INJURY TREATMENT MARKET SIZE, BY NITRIC OXIDE, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 89. GLOBAL ACUTE LUNG INJURY TREATMENT MARKET SIZE, BY NITRIC OXIDE, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 90. GLOBAL ACUTE LUNG INJURY TREATMENT MARKET SIZE, BY NITRIC OXIDE, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 91. GLOBAL ACUTE LUNG INJURY TREATMENT MARKET SIZE, BY NITRIC OXIDE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 92. GLOBAL ACUTE LUNG INJURY TREATMENT MARKET SIZE, BY NITRIC OXIDE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 93. GLOBAL ACUTE LUNG INJURY TREATMENT MARKET SIZE, BY ADMINISTRATION ROUTE, 2018-2024 (USD MILLION)
  • TABLE 94. GLOBAL ACUTE LUNG INJURY TREATMENT MARKET SIZE, BY ADMINISTRATION ROUTE, 2025-2032 (USD MILLION)
  • TABLE 95. GLOBAL ACUTE LUNG INJURY TREATMENT MARKET SIZE, BY INHALATION, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 96. GLOBAL ACUTE LUNG INJURY TREATMENT MARKET SIZE, BY INHALATION, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 97. GLOBAL ACUTE LUNG INJURY TREATMENT MARKET SIZE, BY INHALATION, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 98. GLOBAL ACUTE LUNG INJURY TREATMENT MARKET SIZE, BY INHALATION, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 99. GLOBAL ACUTE LUNG INJURY TREATMENT MARKET SIZE, BY INHALATION, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 100. GLOBAL ACUTE LUNG INJURY TREATMENT MARKET SIZE, BY INHALATION, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 101. GLOBAL ACUTE LUNG INJURY TREATMENT MARKET SIZE, BY INTRAVENOUS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 102. GLOBAL ACUTE LUNG INJURY TREATMENT MARKET SIZE, BY INTRAVENOUS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 103. GLOBAL ACUTE LUNG INJURY TREATMENT MARKET SIZE, BY INTRAVENOUS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 104. GLOBAL ACUTE LUNG INJURY TREATMENT MARKET SIZE, BY INTRAVENOUS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 105. GLOBAL ACUTE LUNG INJURY TREATMENT MARKET SIZE, BY INTRAVENOUS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 106. GLOBAL ACUTE LUNG INJURY TREATMENT MARKET SIZE, BY INTRAVENOUS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 107. GLOBAL ACUTE LUNG INJURY TREATMENT MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 108. GLOBAL ACUTE LUNG INJURY TREATMENT MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
  • TABLE 109. GLOBAL ACUTE LUNG INJURY TREATMENT MARKET SIZE, BY AMBULATORY CARE CENTERS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 110. GLOBAL ACUTE LUNG INJURY TREATMENT MARKET SIZE, BY AMBULATORY CARE CENTERS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 111. GLOBAL ACUTE LUNG INJURY TREATMENT MARKET SIZE, BY AMBULATORY CARE CENTERS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 112. GLOBAL ACUTE LUNG INJURY TREATMENT MARKET SIZE, BY AMBULATORY CARE CENTERS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 113. GLOBAL ACUTE LUNG INJURY TREATMENT MARKET SIZE, BY AMBULATORY CARE CENTERS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 114. GLOBAL ACUTE LUNG INJURY TREATMENT MARKET SIZE, BY AMBULATORY CARE CENTERS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 115. GLOBAL ACUTE LUNG INJURY TREATMENT MARKET SIZE, BY HOSPITALS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 116. GLOBAL ACUTE LUNG INJURY TREATMENT MARKET SIZE, BY HOSPITALS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 117. GLOBAL ACUTE LUNG INJURY TREATMENT MARKET SIZE, BY HOSPITALS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 118. GLOBAL ACUTE LUNG INJURY TREATMENT MARKET SIZE, BY HOSPITALS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 119. GLOBAL ACUTE LUNG INJURY TREATMENT MARKET SIZE, BY HOSPITALS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 120. GLOBAL ACUTE LUNG INJURY TREATMENT MARKET SIZE, BY HOSPITALS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 121. GLOBAL ACUTE LUNG INJURY TREATMENT MARKET SIZE, BY RESEARCH INSTITUTES, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 122. GLOBAL ACUTE LUNG INJURY TREATMENT MARKET SIZE, BY RESEARCH INSTITUTES, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 123. GLOBAL ACUTE LUNG INJURY TREATMENT MARKET SIZE, BY RESEARCH INSTITUTES, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 124. GLOBAL ACUTE LUNG INJURY TREATMENT MARKET SIZE, BY RESEARCH INSTITUTES, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 125. GLOBAL ACUTE LUNG INJURY TREATMENT MARKET SIZE, BY RESEARCH INSTITUTES, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 126. GLOBAL ACUTE LUNG INJURY TREATMENT MARKET SIZE, BY RESEARCH INSTITUTES, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 127. GLOBAL ACUTE LUNG INJURY TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
  • TABLE 128. GLOBAL ACUTE LUNG INJURY TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2032 (USD MILLION)
  • TABLE 129. GLOBAL ACUTE LUNG INJURY TREATMENT MARKET SIZE, BY HOSPITAL PHARMACIES, 2018-2024 (USD MILLION)
  • TABLE 130. GLOBAL ACUTE LUNG INJURY TREATMENT MARKET SIZE, BY HOSPITAL PHARMACIES, 2025-2032 (USD MILLION)
  • TABLE 131. GLOBAL ACUTE LUNG INJURY TREATMENT MARKET SIZE, BY HOSPITAL PHARMACIES, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 132. GLOBAL ACUTE LUNG INJURY TREATMENT MARKET SIZE, BY HOSPITAL PHARMACIES, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 133. GLOBAL ACUTE LUNG INJURY TREATMENT MARKET SIZE, BY HOSPITAL PHARMACIES, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 134. GLOBAL ACUTE LUNG INJURY TREATMENT MARKET SIZE, BY HOSPITAL PHARMACIES, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 135. GLOBAL ACUTE LUNG INJURY TREATMENT MARKET SIZE, BY HOSPITAL PHARMACIES, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 136. GLOBAL ACUTE LUNG INJURY TREATMENT MARKET SIZE, BY HOSPITAL PHARMACIES, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 137. GLOBAL ACUTE LUNG INJURY TREATMENT MARKET SIZE, BY INPATIENT PHARMACIES, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 138. GLOBAL ACUTE LUNG INJURY TREATMENT MARKET SIZE, BY INPATIENT PHARMACIES, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 139. GLOBAL ACUTE LUNG INJURY TREATMENT MARKET SIZE, BY INPATIENT PHARMACIES, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 140. GLOBAL ACUTE LUNG INJURY TREATMENT MARKET SIZE, BY INPATIENT PHARMACIES, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 141. GLOBAL ACUTE LUNG INJURY TREATMENT MARKET SIZE, BY INPATIENT PHARMACIES, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 142. GLOBAL ACUTE LUNG INJURY TREATMENT MARKET SIZE, BY INPATIENT PHARMACIES, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 143. GLOBAL ACUTE LUNG INJURY TREATMENT MARKET SIZE, BY OUTPATIENT PHARMACIES, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 144. GLOBAL ACUTE LUNG INJURY TREATMENT MARKET SIZE, BY OUTPATIENT PHARMACIES, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 145. GLOBAL ACUTE LUNG INJURY TREATMENT MARKET SIZE, BY OUTPATIENT PHARMACIES, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 146. GLOBAL ACUTE LUNG INJURY TREATMENT MARKET SIZE, BY OUTPATIENT PHARMACIES, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 147. GLOBAL ACUTE LUNG INJURY TREATMENT MARKET SIZE, BY OUTPATIENT PHARMACIES, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 148. GLOBAL ACUTE LUNG INJURY TREATMENT MARKET SIZE, BY OUTPATIENT PHARMACIES, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 149. GLOBAL ACUTE LUNG INJURY TREATMENT MARKET SIZE, BY ONLINE PHARMACIES, 2018-2024 (USD MILLION)
  • TABLE 150. GLOBAL ACUTE LUNG INJURY TREATMENT MARKET SIZE, BY ONLINE PHARMACIES, 2025-2032 (USD MILLION)
  • TABLE 151. GLOBAL ACUTE LUNG INJURY TREATMENT MARKET SIZE, BY ONLINE PHARMACIES, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 152. GLOBAL ACUTE LUNG INJURY TREATMENT MARKET SIZE, BY ONLINE PHARMACIES, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 153. GLOBAL ACUTE LUNG INJURY TREATMENT MARKET SIZE, BY ONLINE PHARMACIES, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 154. GLOBAL ACUTE LUNG INJURY TREATMENT MARKET SIZE, BY ONLINE PHARMACIES, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 155. GLOBAL ACUTE LUNG INJURY TREATMENT MARKET SIZE, BY ONLINE PHARMACIES, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 156. GLOBAL ACUTE LUNG INJURY TREATMENT MARKET SIZE, BY ONLINE PHARMACIES, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 157. GLOBAL ACUTE LUNG INJURY TREATMENT MARKET SIZE, BY DIRECT TO PATIENT, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 158. GLOBAL ACUTE LUNG INJURY TREATMENT MARKET SIZE, BY DIRECT TO PATIENT, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 159. GLOBAL ACUTE LUNG INJURY TREATMENT MARKET SIZE, BY DIRECT TO PATIENT, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 160. GLOBAL ACUTE LUNG INJURY TREATMENT MARKET SIZE, BY DIRECT TO PATIENT, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 161. GLOBAL ACUTE LUNG INJURY TREATMENT MARKET SIZE, BY DIRECT TO PATIENT, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 162. GLOBAL ACUTE LUNG INJURY TREATMENT MARKET SIZE, BY DIRECT TO PATIENT, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 163. GLOBAL ACUTE LUNG INJURY TREATMENT MARKET SIZE, BY THIRD PARTY FULFILLMENT, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 164. GLOBAL ACUTE LUNG INJURY TREATMENT MARKET SIZE, BY THIRD PARTY FULFILLMENT, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 165. GLOBAL ACUTE LUNG INJURY TREATMENT MARKET SIZE, BY THIRD PARTY FULFILLMENT, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 166. GLOBAL ACUTE LUNG INJURY TREATMENT MARKET SIZE, BY THIRD PARTY FULFILLMENT, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 167. GLOBAL ACUTE LUNG INJURY TREATMENT MARKET SIZE, BY THIRD PARTY FULFILLMENT, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 168. GLOBAL ACUTE LUNG INJURY TREATMENT MARKET SIZE, BY THIRD PARTY FULFILLMENT, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 169. GLOBAL ACUTE LUNG INJURY TREATMENT MARKET SIZE, BY RETAIL PHARMACIES, 2018-2024 (USD MILLION)
  • TABLE 170. GLOBAL ACUTE LUNG INJURY TREATMENT MARKET SIZE, BY RETAIL PHARMACIES, 2025-2032 (USD MILLION)
  • TABLE 171. GLOBAL ACUTE LUNG INJURY TREATMENT MARKET SIZE, BY RETAIL PHARMACIES, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 172. GLOBAL ACUTE LUNG INJURY TREATMENT MARKET SIZE, BY RETAIL PHARMACIES, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 173. GLOBAL ACUTE LUNG INJURY TREATMENT MARKET SIZE, BY RETAIL PHARMACIES, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 174. GLOBAL ACUTE LUNG INJURY TREATMENT MARKET SIZE, BY RETAIL PHARMACIES, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 175. GLOBAL ACUTE LUNG INJURY TREATMENT MARKET SIZE, BY RETAIL PHARMACIES, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 176. GLOBAL ACUTE LUNG INJURY TREATMENT MARKET SIZE, BY RETAIL PHARMACIES, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 177. GLOBAL ACUTE LUNG INJURY TREATMENT MARKET SIZE, BY CHAIN PHARMACIES, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 178. GLOBAL ACUTE LUNG INJURY TREATMENT MARKET SIZE, BY CHAIN PHARMACIES, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 179. GLOBAL ACUTE LUNG INJURY TREATMENT MARKET SIZE, BY CHAIN PHARMACIES, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 180. GLOBAL ACUTE LUNG INJURY TREATMENT MARKET SIZE, BY CHAIN PHARMACIES, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 181. GLOBAL ACUTE LUNG INJURY TREATMENT MARKET SIZE, BY CHAIN PHARMACIES, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 182. GLOBAL ACUTE LUNG INJURY TREATMENT MARKET SIZE, BY CHAIN PHARMACIES, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 183. GLOBAL ACUTE LUNG INJURY TREATMENT MARKET SIZE, BY INDEPENDENT PHARMACIES, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 184. GLOBAL ACUTE LUNG INJURY TREATMENT MARKET SIZE, BY INDEPENDENT PHARMACIES, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 185. GLOBAL ACUTE LUNG INJURY TREATMENT MARKET SIZE, BY INDEPENDENT PHARMACIES, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 186. GLOBAL ACUTE LUNG INJURY TREATMENT MARKET SIZE, BY INDEPENDENT PHARMACIES, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 187. GLOBAL ACUTE LUNG INJURY TREATMENT MARKET SIZE, BY INDEPENDENT PHARMACIES, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 188. GLOBAL ACUTE LUNG INJURY TREATMENT MARKET SIZE, BY INDEPENDENT PHARMACIES, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 189. GLOBAL ACUTE LUNG INJURY TREATMENT MARKET SIZE, BY PATIENT AGE GROUP, 2018-2024 (USD MILLION)
  • TABLE 190. GLOBAL ACUTE LUNG INJURY TREATMENT MARKET SIZE, BY PATIENT AGE GROUP, 2025-2032 (USD MILLION)
  • TABLE 191. GLOBAL ACUTE LUNG INJURY TREATMENT MARKET SIZE, BY ADULT, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 192. GLOBAL ACUTE LUNG INJURY TREATMENT MARKET SIZE, BY ADULT, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 193. GLOBAL ACUTE LUNG INJURY TREATMENT MARKET SIZE, BY ADULT, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 194. GLOBAL ACUTE LUNG INJURY TREATMENT MARKET SIZE, BY ADULT, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 195. GLOBAL ACUTE LUNG INJURY TREATMENT MARKET SIZE, BY ADULT, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 196. GLOBAL ACUTE LUNG INJURY TREATMENT MARKET SIZE, BY ADULT, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 197. GLOBAL ACUTE LUNG INJURY TREATMENT MARKET SIZE, BY GERIATRIC, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 198. GLOBAL ACUTE LUNG INJURY TREATMENT MARKET SIZE, BY GERIATRIC, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 199. GLOBAL ACUTE LUNG INJURY TREATMENT MARKET SIZE, BY GERIATRIC, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 200. GLOBAL ACUTE LUNG INJURY TREATMENT MARKET SIZE, BY GERIATRIC, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 201. GLOBAL ACUTE LUNG INJURY TREATMENT MARKET SIZE, BY GERIATRIC, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 202. GLOBAL ACUTE LUNG INJURY TREATMENT MARKET SIZE, BY GERIATRIC, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 203. GLOBAL ACUTE LUNG INJURY TREATMENT MARKET SIZE, BY PEDIATRIC, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 204. GLOBAL ACUTE LUNG INJURY TREATMENT MARKET SIZE, BY PEDIATRIC, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 205. GLOBAL ACUTE LUNG INJURY TREATMENT MARKET SIZE, BY PEDIATRIC, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 206. GLOBAL ACUTE LUNG INJURY TREATMENT MARKET SIZE, BY PEDIATRIC, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 207. GLOBAL ACUTE LUNG INJURY TREATMENT MARKET SIZE, BY PEDIATRIC, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 208. GLOBAL ACUTE LUNG INJURY TREATMENT MARKET SIZE, BY PEDIATRIC, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 209. GLOBAL ACUTE LUNG INJURY TREATMENT MARKET SIZE, BY TREATMENT SETTING, 2018-2024 (USD MILLION)
  • TABLE 210. GLOBAL ACUTE LUNG INJURY TREATMENT MARKET SIZE, BY TREATMENT SETTING, 2025-2032 (USD MILLION)
  • TABLE 211. GLOBAL ACUTE LUNG INJURY TREATMENT MARKET SIZE, BY EMERGENCY DEPARTMENT, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 212. GLOBAL ACUTE LUNG INJURY TREATMENT MARKET SIZE, BY EMERGENCY DEPARTMENT, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 213. GLOBAL ACUTE LUNG INJURY TREATMENT MARKET SIZE, BY EMERGENCY DEPARTMENT, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 214. GLOBAL ACUTE LUNG INJURY TREATMENT MARKET SIZE, BY EMERGENCY DEPARTMENT, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 215. GLOBAL ACUTE LUNG INJURY TREATMENT MARKET SIZE, BY EMERGENCY DEPARTMENT, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 216. GLOBAL ACUTE LUNG INJURY TREATMENT MARKET SIZE, BY EMERGENCY DEPARTMENT, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 217. GLOBAL ACUTE LUNG INJURY TREATMENT MARKET SIZE, BY GENERAL WARD, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 218. GLOBAL ACUTE LUNG INJURY TREATMENT MARKET SIZE, BY GENERAL WARD, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 219. GLOBAL ACUTE LUNG INJURY TREATMENT MARKET SIZE, BY GENERAL WARD, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 220. GLOBAL ACUTE LUNG INJURY TREATMENT MARKET SIZE, BY GENERAL WARD, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 221. GLOBAL ACUTE LUNG INJURY TREATMENT MARKET SIZE, BY GENERAL WARD, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 222. GLOBAL ACUTE LUNG INJURY TREATMENT MARKET SIZE, BY GENERAL WARD, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 223. GLOBAL ACUTE LUNG INJURY TREATMENT MARKET SIZE, BY INTENSIVE CARE UNIT, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 224. GLOBAL ACUTE LUNG INJURY TREATMENT MARKET SIZE, BY INTENSIVE CARE UNIT, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 225. GLOBAL ACUTE LUNG INJURY TREATMENT MARKET SIZE, BY INTENSIVE CARE UNIT, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 226. GLOBAL ACUTE LUNG INJURY TREATMENT MARKET SIZE, BY INTENSIVE CARE UNIT, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 227. GLOBAL ACUTE LUNG INJURY TREATMENT MARKET SIZE, BY INTENSIVE CARE UNIT, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 228. GLOBAL ACUTE LUNG INJURY TREATMENT MARKET SIZE, BY INTENSIVE CARE UNIT, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 229. GLOBAL ACUTE LUNG INJURY TREATMENT MARKET SIZE, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 230. GLOBAL ACUTE LUNG INJURY TREATMENT MARKET SIZE, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 231. AMERICAS ACUTE LUNG INJURY TREATMENT MARKET SIZE, BY SUBREGION, 2018-2024 (USD MILLION)
  • TABLE 232. AMERICAS ACUTE LUNG INJURY TREATMENT MARKET SIZE, BY SUBREGION, 2025-2032 (USD MILLION)
  • TABLE 233. AMERICAS ACUTE LUNG INJURY TREATMENT MARKET SIZE, BY DRUG CLASS, 2018-2024 (USD MILLION)
  • TABLE 234. AMERICAS ACUTE LUNG INJURY TREATMENT MARKET SIZE, BY DRUG CLASS, 2025-2032 (USD MILLION)
  • TABLE 235. AMERICAS ACUTE LUNG INJURY TREATMENT MARKET SIZE, BY CORTICOSTEROIDS, 2018-2024 (USD MILLION)
  • TABLE 236. AMERICAS ACUTE LUNG INJURY TREATMENT MARKET SIZE, BY CORTICOSTEROIDS, 2025-2032 (USD MILLION)
  • TABLE 237. AMERICAS ACUTE LUNG INJURY TREATMENT MARKET SIZE, BY NEUROMUSCULAR BLOCKING AGENTS, 2018-2024 (USD MILLION)
  • TABLE 238. AMERICAS ACUTE LUNG INJURY TREATMENT MARKET SIZE, BY NEUROMUSCULAR BLOCKING AGENTS, 2025-2032 (USD MILLION)
  • TABLE 239. AMERICAS ACUTE LUNG INJURY TREATMENT MARKET SIZE, BY SURFACTANTS, 2018-2024 (USD MILLION)
  • TABLE 240. AMERICAS ACUTE LUNG INJURY TREATMENT MARKET SIZE, BY SURFACTANTS, 2025-2032 (USD MILLION)
  • TABLE 241. AMERICAS ACUTE LUNG INJURY TREATMENT MARKET SIZE, BY VASODILATORS, 2018-2024 (USD MILLION)
  • TABLE 242. AMERICAS ACUTE LUNG INJURY TREATMENT MARKET SIZE, BY VASODILATORS, 2025-2032 (USD MILLION)
  • TABLE 243. AMERICAS ACUTE LUNG INJURY TREATMENT MARKET SIZE, BY ADMINISTRATION ROUTE, 2018-2024 (USD MILLION)
  • TABLE 244. AMERICAS ACUTE LUNG INJURY TREATMENT MARKET SIZE, BY ADMINISTRATION ROUTE, 2025-2032 (USD MILLION)
  • TABLE 245. AMERICAS ACUTE LUNG INJURY TREATMENT MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 246. AMERICAS ACUTE LUNG INJURY TREATMENT MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
  • TABLE 247. AMERICAS ACUTE LUNG INJURY TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
  • TABLE 248. AMERICAS ACUTE LUNG INJURY TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2032 (USD MILLION)
  • TABLE 249. AMERICAS ACUTE LUNG INJURY TREATMENT MARKET SIZE, BY HOSPITAL PHARMACIES, 2018-2024 (USD MILLION)
  • TABLE 250. AMERICAS ACUTE LUNG INJURY TREATMENT MARKET SIZE, BY HOSPITAL PHARMACIES, 2025-2032 (USD MILLION)
  • TABLE 251. AMERICAS ACUTE LUNG INJURY TREATMENT MARKET SIZE, BY ONLINE PHARMACIES, 2018-2024 (USD MILLION)
  • TABLE 252. AMERICAS ACUTE LUNG INJURY TREATMENT MARKET SIZE, BY ONLINE PHARMACIES, 2025-2032 (USD MILLION)
  • TABLE 253. AMERICAS ACUTE LUNG INJURY TREATMENT MARKET SIZE, BY RETAIL PHARMACIES, 2018-2024 (USD MILLION)
  • TABLE 254. AMERICAS ACUTE LUNG INJURY TREATMENT MARKET SIZE, BY RETAIL PHARMACIES, 2025-2032 (USD MILLION)
  • TABLE 255. AMERICAS ACUTE LUNG INJURY TREATMENT MARKET SIZE, BY PATIENT AGE GROUP, 2018-2024 (USD MILLION)
  • TABLE 256. AMERICAS ACUTE LUNG INJURY TREATMENT MARKET SIZE, BY PATIENT AGE GROUP, 2025-2032 (USD MILLION)
  • TABLE 257. AMERICAS ACUTE LUNG INJURY TREATMENT MARKET SIZE, BY TREATMENT SETTING, 2018-2024 (USD MILLION)
  • TABLE 258. AMERICAS ACUTE LUNG INJURY TREATMENT MARKET SIZE, BY TREATMENT SETTING, 2025-2032 (USD MILLION)
  • TABLE 259. NORTH AMERICA ACUTE LUNG INJURY TREATMENT MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 260. NORTH AMERICA ACUTE LUNG INJURY TREATMENT MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 261. NORTH AMERICA ACUTE LUNG INJURY TREATMENT MARKET SIZE, BY DRUG CLASS, 2018-2024 (USD MILLION)
  • TABLE 262. NORTH AMERICA ACUTE LUNG INJURY TREATMENT MARKET SIZE, BY DRUG CLASS, 2025-2032 (USD MILLION)
  • TABLE 263. NORTH AMERICA ACUTE LUNG INJURY TREATMENT MARKET SIZE, BY CORTICOSTEROIDS, 2018-2024 (USD MILLION)
  • TABLE 264. NORTH AMERICA ACUTE LUNG INJURY TREATMENT MARKET SIZE, BY CORTICOSTEROIDS, 2025-2032 (USD MILLION)
  • TABLE 265. NORTH AMERICA ACUTE LUNG INJURY TREATMENT MARKET SIZE, BY NEUROMUSCULAR BLOCKING AGENTS, 2018-2024 (USD MILLION)
  • TABLE 266. NORTH AMERICA ACUTE LUNG INJURY TREATMENT MARKET SIZE, BY NEUROMUSCULAR BLOCKING AGENTS, 2025-2032 (USD MILLION)
  • TABLE 267. NORTH AMERICA ACUTE LUNG INJURY TREATMENT MARKET SIZE, BY SURFACTANTS, 2018-2024 (USD MILLION)
  • TABLE 268. NORTH AMERICA ACUTE LUNG INJURY TREATMENT MARKET SIZE, BY SURFACTANTS, 2025-2032 (USD MILLION)
  • TABLE 269. NORTH AMERICA ACUTE LUNG INJURY TREATMENT MARKET SIZE, BY VASODILATORS, 2018-2024 (USD MILLION)
  • TABLE 270. NORTH AMERICA ACUTE LUNG INJURY TREATMENT MARKET SIZE, BY VASODILATORS, 2025-2032 (USD MILLION)
  • TABLE 271. NORTH AMERICA ACUTE LUNG INJURY TREATMENT MARKET SIZE, BY ADMINISTRATION ROUTE, 2018-2024 (USD MILLION)
  • TABLE 272. NORTH AMERICA ACUTE LUNG INJURY TREATMENT MARKET SIZE, BY ADMINISTRATION ROUTE, 2025-2032 (USD MILLION)
  • TABLE 273. NORTH AMERICA ACUTE LUNG INJURY TREATMENT MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 274. NORTH AMERICA ACUTE LUNG INJURY TREATMENT MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
  • TABLE 275. NORTH AMERICA ACUTE LUNG INJURY TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
  • TABLE 276. NORTH AMERICA ACUTE LUNG INJURY TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2032 (USD MILLION)
  • TABLE 277. NORTH AMERICA ACUTE LUNG INJURY TREATMENT MARKET SIZE, BY HOSPITAL PHARMACIES, 2018-2024 (USD MILLION)
  • TABLE 278. NORTH AMERICA ACUTE LUNG INJURY TREATMENT MARKET SIZE, BY HOSPITAL PHARMACIES, 2025-2032 (USD MILLION)
  • TABLE 279. NORTH AMERICA ACUTE LUNG INJURY TREATMENT MARKET SIZE, BY ONLINE PHARMACIES, 2018-2024 (USD MILLION)
  • TABLE 280. NORTH AMERICA ACUTE LUNG INJURY TREATMENT MARKET SIZE, BY ONLINE PHARMACIES, 2025-2032 (USD MILLION)
  • TABLE 281. NORTH AMERICA ACUTE LUNG INJURY TREATMENT MARKET SIZE, BY RETAIL PHARMACIES, 2018-2024 (USD MILLION)
  • TABLE 282. NORTH AMERICA ACUTE LUNG INJURY TREATMENT MARKET SIZE, BY RETAIL PHARMACIES, 2025-2032 (USD MILLION)
  • TABLE 283. NORTH AMERICA ACUTE LUNG INJURY TREATMENT MARKET SIZE, BY PATIENT AGE GROUP, 2018-2024 (USD MILLION)
  • TABLE 284. NORTH AMERICA ACUTE LUNG INJURY TREATMENT MARKET SIZE, BY PATIENT AGE GROUP, 2025-2032 (USD MILLION)
  • TABLE 285. NORTH AMERICA ACUTE LUNG INJURY TREATMENT MARKET SIZE, BY TREATMENT SETTING, 2018-2024 (USD MILLION)
  • TABLE 286. NORTH AMERICA ACUTE LUNG INJURY TREATMENT MARKET SIZE, BY TREATMENT SETTING, 2025-2032 (USD MILLION)
  • TABLE 287. LATIN AMERICA ACUTE LUNG INJURY TREATMENT MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 288. LATIN AMERICA ACUTE LUNG INJURY TREATMENT MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 289. LATIN AMERICA ACUTE LUNG INJURY TREATMENT MARKET SIZE, BY DRUG CLASS, 2018-2024 (USD MILLION)
  • TABLE 290. LATIN AMERICA ACUTE LUNG INJURY TREATMENT MARKET SIZE, BY DRUG CLASS, 2025-2032 (USD MILLION)
  • TABLE 291. LATIN AMERICA ACUTE LUNG INJURY TREATMENT MARKET SIZE, BY CORTICOSTEROIDS, 2018-2024 (USD MILLION)
  • TABLE 292. LATIN AMERICA ACUTE LUNG INJURY TREATMENT MARKET SIZE, BY CORTICOSTEROIDS, 2025-2032 (USD MILLION)
  • TABLE 293. LATIN AMERICA ACUTE LUNG INJURY TREATMENT MARKET SIZE, BY NEUROMUSCULAR BLOCKING AGENTS, 2018-2024 (USD MILLION)
  • TABLE 294. LATIN AMERICA ACUTE LUNG INJURY TREATMENT MARKET SIZE, BY NEUROMUSCULAR BLOCKING AGENTS, 2025-2032 (USD MILLION)
  • TABLE 295. LATIN AMERICA ACUTE LUNG INJURY TREATMENT MARKET SIZE, BY SURFACTANTS, 2018-2024 (USD MILLION)
  • TABLE 296. LATIN AMERICA ACUTE LUNG INJURY